The FDA on August 6, 2025, granted accelerated approval to MODEYSO®, a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. MODEYSO® is a product of Jazz Pharmaceuticals, Inc.
Bottom Ad
Advertisement
Subscribe
